secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2023-12-29T23:59:59+00:00
Accession:  0001493152-23-046468
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics completes acquisition of Odyssey's concussion, NPC drug assets for $1M cash + 8M preferred shares
--------------------------------------------------------------------------------

- Paid $1M cash and issued 8M Series F Preferred shares to Odyssey for assets including mTBI (concussion) and NPC drug candidates and nasal delivery device.
- Joseph Michael Redmond appointed President with $396,000 base salary, eligible for 50% performance bonus, and 75,000 stock options at $5.40.
- Kimberly Murphy remains CEO and board member; Redmond reports to her.
- Series F Preferred is convertible into common stock; further details in prior 8-K from October 5, 2023.
- Employment agreement has 1-year initial term with automatic renewal; severance includes 6-12 months base salary under certain conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315223046468/0001493152-23-046468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315223046468/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-046468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer